The Pathophysiology of The Antiphospholipid Syndrome: A Perspective From The Blood Coagulation System

• Published in: Clinical and Applied Thrombosis/Hemostasis Vol. 28; p. 10760296221088576
• Main Authors: Arreola-Diaz, R, Majluf-Cruz, A, Sanchez-Torres, LE, Hernandez-Juarez, J
• Format: Book Review Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01.03.2022; SAGE PUBLICATIONS, INC; SAGE Publishing
• Subjects: Antibodies; Antiphospholipid Syndrome - complications; Autoimmune diseases; Blood Coagulation; Endothelial Cells; Female; Humans; Neutrophils; Placenta; Pregnancy; Review; Thrombosis; Tissue Plasminogen Activator; antiphospholipid syndrome; thrombosis; autoimmunity; miscarriage; autoantibodies
• ISSN: 1076-0296; 1938-2723
• DOI: 10.1177/10760296221088576

The antiphospholipid syndrome (APS), a systemic autoimmune disease characterized by a hypercoagulability associated to vascular thrombosis and/or obstetric morbidity, is caused by the presence of antiphospholipid antibodies such as lupus anticoagulant, anti-β-2-glycoprotein 1, and/or anticardiolipin antibodies. In the obstetrical APS, antiphospholipid antibodies induce the production of proinflammatory cytokines and tissue factor by placental tissues and recruited neutrophils. Moreover, antiphospholipid antibodies activate the complement system which, in turn, induces a positive feedback leading to recruitment of neutrophils as well as activation of the placenta. Activation of these cells triggers myometrial contractions and cervical ripening provoking the induction of labor. In thrombotic and obstetrical APS, antiphospholipid antibodies activate endothelial cells, platelets, and neutrophils and they may alter the multimeric pattern and concentration of von Willebrand factor, increase the concentration of thrombospondin 1, reduce the inactivation of factor XI by antithrombin, increase the activation of factor XII, and reduce the activity of tissue plasminogen activator with the subsequent production of plasmin. All these effects result in less permeable clots, denser, thinner, and with more branched fibrin fibers which are more difficult to lysate. As a consequence, thrombosis, the defining clinical criterion of APS, complicates the clinical course of the patient.